

WHAT IS CLAIMED IS:

- 1 1. A method of treating a subject having a pathologic condition
2 involving neovascularization comprising administering a pharmaceutical preparation
3 comprising an R'-Glu-Trp-R" dipeptide and a pharmaceutically acceptable carrier to the
4 subject in an amount effective to inhibit neovascularization.
- 1 2. The method of claim 1 wherein the R'-Glu-Trp-R" dipeptide is L-
2 Glu-L-Trp.
- 1 3. The method of claim 2 wherein the condition is hemangioma.
- 1 4. The method of claim 2 wherein the condition is vascularized
2 malignant tumor or vascularized benign tumor.
- 1 5. The method of claim 2 wherein the condition is neovascularization
2 in post-recovery cerebrovascular accident; neovascularization due to head trauma;
3 restenosis following angioplasty; or neovascularization due to heat or cold trauma.
- 1 6. The method of claim 2 wherein the condition is neovascularization
2 associated with substance-induced neovascularization of the liver, angiogenic
3 dysfunction related to an excess of hormone; neovascular sequelae of diabetes;
4 neovascular sequelae to hypertension; or chronic liver infection.
- 1 7. The method of claim 2 comprising administering to the subject a
2 dose of about 0.5 μ g per 1 kilogram body weight to about 1 mg per 1 kg body weight.
- 1 8. The method of claim 7 wherein the effective amount is about
2 1 μ g/kg to about 50 μ g/kg body weight.
- 1 9. The method of claim 7 wherein the dose is administered daily
2 over a period of 1 day to about 30 days.

1 10. The method of claim 7 wherein the pharmaceutical preparation is
2 administered intramuscularly or intranasally.

1 11. The method of claim 2 comprising administering the
2 pharmaceutical preparation in the form of an injectable solution containing 0.001% to
3 0.01% of L-Glu-L-Trp.

1 12. The method of claim 2 comprising administering the preparation
2 in a unit dose form comprising a tablet, a suppository, a capsule, an eye film, an
3 inhalant, a mucosal spray, a nose drop, an eye drop, a toothpaste, an ointment, or water
4 soluble based cream.

1 13. The method of claim 12 wherein said unit dose form consists
2 essentially of 0.01 mg of said R'-Glu-Trp-R".

1 14. The method of claim 2 further comprising administering to the
2 subject a vasoactive drug.

1 15. The method of claim 14 wherein the vasoactive drug is an
2 angiotensin converting enzyme (ACE) inhibitor or a potassium channel opener (PCO).

1 16. The method of claim 2 wherein the subject suffers from a tumor
2 wherein the method further comprises administering a chemotherapeutic agent.

1 17. The method of claim 2 wherein the subject is not immune
2 compromised.

add
4B1
F3